Results 251 to 260 of about 927,420 (325)
2025 Egyptian guidelines for the management of dyslipidemia. [PDF]
Reda A +9 more
europepmc +1 more source
ABSTRACT Objective Bile acids are indispensable modulators in the development of polycystic ovary syndrome (PCOS). Our previous study identified that metformin and canagliflozin have similar efficacy in patients with PCOS combined with insulin resistance (IR).
Qi Yan +8 more
wiley +1 more source
Combined Impact of Mean and Variability of Non-HDL Cholesterol on Myocardial Infarction in Hemodialysis Patients. [PDF]
Lee H +7 more
europepmc +1 more source
ABSTRACT Type 2 diabetes (T2D) is a progressive metabolic disorder that could be an underlying cause of long‐term complications that increase mortality. The assessment of the probability of such events could be essential for mortality risk management. This work aimed to establish a framework for risk predictions of macrovascular complications (MVC) and
Hanna Kunina +2 more
wiley +1 more source
ABSTRACT Ashwagandha, an adaptogen, is an important herb of Ayurveda used as a Rasayana for its various health benefits. This prospective, multi‐center, observational clinical study evaluates the safety (clinical and laboratory) of a standardized Ashwagandha Root Extract (ARE) on long‐term administration over 12 months. Male and female adults (N = 191)
Jaising Salve +6 more
wiley +1 more source
High-density lipoprotein-related inflammation indices and reproductive lifespan in women: insights from NHANES 2007-2018. [PDF]
Liao J +5 more
europepmc +1 more source
Baicalin restores the hypoglycemic effect of metformin by decreasing the serum imidazole propionate. ABSTRACT Gut microbiota dysbiosis is implicated in metformin non‐response. This study aimed to investigate whether baicalin, a microbiota‐modulating flavonoid derived from Radix Scutellariae, could restore metformin sensitivity and explored the ...
Aiting Wang +5 more
wiley +1 more source
Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias. [PDF]
Kosmas CE +4 more
europepmc +1 more source
Hepatic fibrosis and metabolic syndrome are more prevalent in PsA patients treated with methotrexate, compared to RA patients. Metabolic syndrome is associated with the risk of hepatic fibrosis in patients diagnosed with PsA and RA even after adjustment forcumulative methotrexate exposure.
Ratchaya Lertnawapan +3 more
wiley +1 more source

